H.C. Wainwright raised the firm’s price target on Stoke Therapeutics (STOK) to $47 from $35 and keeps a Buy rating on the shares. Stoke and Biogen (BIIB) announced a collaboration deal on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback